Overview

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

Phase:

Phase 3

Details

Lead Sponsor:

Alcon Research

Treatments:

Anecortave